Introduction {#s1}
============

Selenium is a trace element essential for essential health that has been suggested to play a preventive role for a variety of chronic diseases, including various cancers \[[@B1]-[@B6]\]. This is likely due to the role of selenium as a constituent of various proteins, known as the selenoproteins \[[@B2],[@B7]\]. Selenoproteins are a class of approximately 25 proteins containing a selenocysteine (SEC) residue. SEC is a cysteine analogue, where sulfur has been replaced by a selenium atom, synthesized from serine bound to a tRNA \[[@B8]\]. The incorporation of SEC is a complex process requiring an in-frame UGA codon, occurring as a stop codon, which is recognized as a SEC codon with the aid of a stem loop called a SEC insertion sequence (SECIS) and several other trans-acting factors \[[@B8],[@B9]\].

The known human selenoproteins include the glutathione peroxidases (GPX), thioredoxin reductases (TXNRD), iodothyronine deiodinases (DIO), and selenophosphate synthetases 2 (SPS2) \[[@B10]\]. The other identified selenoproteins include, but are not limited to, selenoprotein n (SEPN1), selenoprotein p (SEPP1), selenoprotein s (SELS), selenoprotein w (SEPW1), and a 15-kDA selenoprotein (SEP15) \[[@B4],[@B10]\]. Not all identified selenoproteins have been characterized; however, many of the selenoproteins with known function (including the GPXs, TXNRDs, SPS2, and DIOs), have redox functions \[[@B10]\] and behave as antioxidants \[[@B1]\] to reduce oxidative stress.

In this study we evaluated single nucleotide polymorphisms (SNPs) in several selenoprotein coding genes for an association with breast cancer: glutathione peroxidase 1 (*GPX1*), glutathione peroxidase 2 (*GPX2*), glutathione peroxidase 3 (*GPX3*), glutathione peroxidase 4 (*GPX4*), *SELS, SEP15, SEPN1, SEPP1, SEPW1*, thioredoxin reductase 1 (*TXNRD1*), and thioredoxin reductase 2 (*TXNRD2*). These selenoproteins were selected for analysis because their functions have been characterized and many of them have been associated with risk of various types of cancer and/or oxidative stress \[[@B2]-[@B7],[@B9],[@B11]-[@B14]\]. The glutathione peroxidases (GPX1, GPX2, GPX3, and GPX4) primarily function to reduce oxidative stress by detoxifying hydrogen peroxide and other organic peroxides \[[@B2],[@B13]\]. SELS is involved in inflammatory response \[[@B10]\]. SEP15 is a protein located primarily in the endoplasmic reticulum and plays a role in protein folding \[[@B2]\]. SEPN1 plays a role in redox homeostasis and protects against oxidative stress \[[@B15]\]. SEPP1 acts as a selenium transport protein, a heavy-metal chelator, and an antioxidant \[[@B10]\]. SEPW1 is a highly conserved protein that acts as an antioxidant protecting against oxidative stress \[[@B10]\]. The thioredoxin reductases (TXNRD1 and TXNRD2) are antioxidants that reduce the oxidized form of thioredoxin, an important regulator of redox-controlled cell functions and redox balance \[[@B12]\]. While many of these selenoprotein-coding genes have been associated with certain cancers, their association with breast cancer remains unclear.

In addition to evaluating SNPs in these genes for an association with breast cancer risk and survival, we also evaluated associations by level of Native American (NA) genetic ancestry. Higher levels of NA ancestry have been associated with reduced breast cancer risk \[[@B16],[@B17]\] and serum selenium concentration has been shown to differ amongst racial and ethnic groups \[[@B18]\]. We also evaluated breast cancer associations by menopausal status and estrogen receptor (ER) and progesterone receptor (PR) status. Additionally, we evaluated breast cancer associations by dietary oxidative balance score (DOBS) since selenoprotein genes may interact with dietary factors that influence oxidative stress.

Methods {#s2}
=======

Ethics Statement {#s2.1}
----------------

All participants signed informed written consent prior to participation and each study was approved by the Institutional Review Board for Human Subjects at the participating institutions: University of Utah, University of Arizona, University of Colorado, University of New Mexico, Comisión de ética, and Institutional Review Board of the Cancer Prevention Institute of California.

Study Design {#s2.2}
------------

The Breast Cancer Health Disparities Study includes participants from three population-based case-control studies, the 4-Corners Breast Cancer Study, the Mexico Breast Cancer Study, and the San Francisco Bay Area Breast Cancer Study \[[@B17]\] who completed an in-person interview and who had a blood or mouthwash sample available for DNA extraction. In the 4- Corners Breast Cancer Study, participants were between 25 and 79 years of age with a histological confirmed diagnosis of *in situ* (n=341) or invasive (n=1492) cancer between October 1999 and May 2004; controls were selected from the target populations of cases living in Arizona, Colorado, New Mexico, and Utah and were frequency matched to cases on ethnicity and 5-year age distribution \[[@B19]\]. Participants from the Mexico Breast Cancer Study were between 28 and 74 years of age. Eligible cases in Mexico were women diagnosed with either a new histologically confirmed *in situ* or invasive breast cancer between January 2004 and December 2007 at 12 participating hospitals from three main health care systems; controls were randomly selected from the catchment area as the cases and frequency matched to cases based on 5-year age distribution, membership in health care institution, and place of residence. The San Francisco Bay Area Breast Cancer Study included women aged 35 to 79 years from the San Francisco Bay Area diagnosed with a first primary histologically confirmed invasive breast cancer between April 1995 and April 2002; controls were identified by random-digit dialing and frequency-matched to cases based on the expected race/ethnicity and 5-year age distribution \[[@B20],[@B21]\].

Data Harmonization {#s2.3}
------------------

Data were harmonized across all study centers and questionnaires as previously described \[[@B17]\]. Women were classified as either pre-menopausal or post-menopausal based on responses to questions on menstrual history. Women who reported still having periods during the referent year (defined as the year before diagnosis for cases or before selection into the study for controls) were classified as pre-menopausal. Center-specific definitions were used to define post-menopausal women. Women were classified as post-menopausal if they reported either a natural menopause or if they reported taking hormone therapy and were still having periods or were at or above the 95th percentile of age for those who reported having a natural menopause (i.e., \> 12 months since their last period. This age at menopause was site-specific by ethnicity: 58 years for NHW and 56 for Hispanic/Native women from the 4-Corners' Breast Cancer Study; 54 for the Mexico Breast Cancer Study; and 55 for NHW and 56 for Hispanic women from the San Francisco Bay Area Breast Cancer Study.

A dietary oxidative balance score (DOBS) that included nutrients with anti- or pro-oxidative balance properties was developed as previously reported \[[@B22]\]. Anti-oxidants included in the score were vitamin C, vitamin E, beta carotene (data for beta carotene were not available for Mexico), folic acid, and dietary fiber; alcohol was treated as a pro-oxidant. Nutrients per 1000 calories were evaluated and quartiles of intake were based on study-specific distributions; Long-term alcohol consumption was classified into three levels: the top 25^th^ percentile of consumption, all other drinkers, and non-drinkers. Referent year alcohol consumption was used for those women who did not have long-term alcohol measurements. In creating the DOBS, participants were assigned values of zero for low levels (first quartile) of exposure to anti-oxidants or high exposure to pro-oxidants (fourth quartile), one for intermediate levels (second and third quartiles) of exposure, and two for high levels (fourth quartile) of exposure to anti-oxidants and low exposure (first quartile) to pro-oxidants.

Genetic Data {#s2.4}
------------

DNA was extracted from either whole blood (n=7287) or mouthwash (n=634) samples. Whole Genome Amplification (WGA) was applied to the mouthwash-derived DNA samples prior to genotyping. A tagSNP approach was used to characterize variation across candidate genes. TagSNPs were selected using the following parameters: linkage disequilibrium (LD) blocks were defined using a Caucasian LD map and an r^2^=0.8; minor allele frequency (MAF) \>0.1; range= -1500 bps from the initiation codon to +1500 bps from the termination codon; and 1 SNP/LD bin. We distinguished European and NA ancestry in the study population by using 104 Ancestry Informative Markers (AIMs) \[[@B17]\]. A multiplexed bead array assay format based on GoldenGate chemistry (Illumina, San Diego, California) was used for genotyping. A genotyping call rate of 99.93% was attained (99.65% for WGA samples). We included 132 blinded internal replicates representing 1.6% of the sample set.  The duplicate concordance rate was 99.996% as determined by 193,297 matching genotypes among sample pairs.  In the current analysis we evaluated *GPX1* (2 SNPs), *GPX2* (4 SNPs), *GPX3* (3 SNPs), *GPX4* (1 SNP)*, SEPP1* (2 candidate SNPs and 1 tagSNP)*, SELS* (2 SNPs), *SEP15* (4 SNPs), *SEPN1* (5 SNPs), *SEPW1* (3 SNPs), *TXNRD1* (7 SNPs), and *TXNRD2* (20 SNPs). A description of these genes and SNPs is shown in online [Table S1](#pone.0080554.s001){ref-type="supplementary-material"}. *SEP15* rs9433110 was not analyzed since it was not in Hardy-Weinberg Equilibrium (HWE) among NHW participants. Online [Table S2](#pone.0080554.s002){ref-type="supplementary-material"} shows minor allele frequency (MAF) and HWE by ancestry groups. It should be noted that in most instances a trend in a different prevalence of MAF across ancestry groups was noted and in some instances, such as *SEPP1* rs6865453, we observed a reversal in the major and minor allele from the most European to the most Native ancestry groups.

Tumor Characteristics and Survival {#s2.5}
----------------------------------

Data for survival and ER/PR tumor status were available for cases from the 4-Corners Breast Cancer Study and the San Francisco Bay Area Breast Cancer Study.

Information on stage at diagnosis, months of survival after diagnosis, cause of death, and ER and PR status were available from cancer registries in Utah, Colorado, Arizona, New Mexico, and California. Information on ER and PR status of tumors was available for 1019 (69%) NHW and 977 (75%) Hispanic/NA cases. Surveillance Epidemiology and End Results (SEER) summary disease stage, based on three codes of local, regional, and distant, was used. Data on survival and ER and PR tumor status were not available from the Mexico Breast Cancer Study.

Statistical Methods {#s2.6}
-------------------

### Genetic Ancestry Estimation {#s2.6.1}

The program STRUCTURE was used to compute individual ancestry for each study participant assuming two founding populations \[[@B23],[@B24]\]. A three-founding population model was assessed but did not fit the population structure with the same level of repeatability and correlation among runs as the two-founding population model. Participants were classified by level of percent NA ancestry. Assessment across categories of ancestry was done using cut-points based on the distribution of genetic ancestry in the control population. These cut-points, 0-28%, \>28-70%, and \>70-100%, maximized power within all three ancestry groups to assess ancestry-specific associations. Genetic ancestry was used as a continuous variable when included in the models to adjust for possible confounding.

### SNP Associations {#s2.6.2}

Genes and SNPs were assessed for their association with breast cancer risk by strata of menopausal status and genetic ancestry in the whole population and by ER/PR status for the 4-Corners Breast Cancer Study and the San Francisco Bay Area Study. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) unless otherwise noted. Logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for breast cancer risk associated with SNPs, adjusting for age, study center, genetic ancestry, body mass index (BMI of kg/m^2^) during referent year, and parity. The generalized logit link function was used when estimating breast cancer risk by ER/PR status. Associations with SNPs were assessed assuming co-dominant models. Based on the initial assessment, SNPs which appeared to have a dominant or recessive mode of inheritance were evaluated with those inheritance models in subsequent analyses. Stratified analyses tests for interactions were calculated using a 1 degree of freedom (df) Wald chi-square tests; p values based on 4-df Wald tests measure the overall SNP (treated as continuous) association with breast cancer risk by ER/PR status. Adjustments for multiple comparisons within the gene used the step-down Bonferroni correction (i.e., Holm method) taking into account the correlated nature of the data using the SNP spectral decomposition method proposed by Nyholt \[[@B25]\] and modified by Li and Ji \[[@B26]\].

### Survival Analysis {#s2.6.3}

Survival months were calculated based on month and year of diagnosis and month and year of death or date of last contact by the cancer registries. Associations between SNPs and risk of dying of breast cancer among primary invasive cases were evaluated using Cox proportional hazards models to obtain multivariate hazard ratios (HR) and 95% CI among all cases and by genetic ancestry strata. The upper two ancestry strata were combined to evaluate survival by ancestry groups since survival data were not available for the Mexico study site. In the analysis of breast cancer survival, individuals were censored when they died of causes other than breast cancer or were lost to follow-up. In addition to the minimal adjustments for age, study center, genetic ancestry, BMI during referent year, and parity, models were also adjusted for SEER summary stage.

### ARTP Analysis {#s2.6.4}

We used the adaptive rank truncated product (ARTP) method that is based on a highly efficient permutation algorithm to determine the significance of association of each gene and of the pathway with breast cancer overall, by genetic ancestry, and by ER/PR strata. The gene p values were generated using the ARTP package in R, permuting outcome status 10,000 times while adjusting for age, BMI during referent year, and genetic ancestry \[[@B27],[@B28]\]. The ARTP method was also applied to survival data using Cox proportional hazard models in R with an additional adjustment for SEER summary stage to generate p values based on likelihood ratio tests. The survival outcome (i.e., vital status and survival months) was permuted 10,000 times in R. We report both pathway and gene p values (P~ARTP~).

Results {#s3}
=======

The overall selenoprotein pathway P~ARTP~ was not significantly associated with breast cancer risk (P~ARTP~ = 0.69), and the association with only one gene, *GPX3*, was of borderline significance for the entire population (P~ARTP~ =0.09). However, we observed several significant associations prior to adjustment for multiple comparisons between selenoprotein SNPs and breast cancer risk ([Table 1](#pone-0080554-t001){ref-type="table"}). *GPX3* rs8177447 (p=0.009, p~adj~=0.02) was associated with breast cancer risk for the entire population. *GPX3* was marginally significant among individuals with ≤28% NA ancestry (P~ARTP~ =0.06) and *SEPP1* was significant among those with \>28% NA ancestry (P~ARTP~ =0.002). The overall pathway was statistically significant (P~ARTP~ =0.04) among women with higher NA ancestry mainly because of the strong association with *SEPP1* and breast cancer risk. *GPX3* rs8177447 (p=0.014, p~adj~ =0.035) and *SELS* rs4965814 (p=0.046, p~adj~ =0.06) were significant among individuals of [\<]{.ul}28% NA ancestry; *SEPP1* rs230812 (p=0.025, p~adj~ = 0.04), and *SEPP1* rs6865453 (p=0.002, p~adj~ = 0.005) were associated with breast cancer risk in individuals of 28-70% NA ancestry; and *SEPN1* rs718391 (p=0.02, p~adj~ =0.09) was marginally associated with breast cancer risk among women of \>70% NA ancestry. Associations were similar for women with \>28% NA ancestry for *SEPP1* rs230812 and rs6865453; when combining the upper ancestry groups these two SNPs were statistically significant (OR=1.33, 95% CI 1.09,1.64 and OR=0.80, 95% CI 0.66,0.96, respectively). Despite apparent differences between SNP associations and breast cancer risk among different NA ancestry groups, only *SEPN1* rs718391 (p=0.03 p~adj~ =0.10), *SEPP1* rs230812 (p=0.005, p~adj~ = 0.008), and *SEPP1* rs6865453 (p=\<0.001, p~adj~ = 0.002) showed significant interaction by ancestry.

10.1371/journal.pone.0080554.t001

###### Associations between selenoprotein genes and breast cancer risk by genetic ancestry.

                                                                                                  Everyone                                     0 - 28% Native American Ancestry            \>28 - 70% Native American Ancestry                  \>70 - 100% Native American Ancestry          Interaction P-value                                                                                                                                                          
  ---------------------------------------------------------- ------------------------------------ ------------------------------------- ------ ---------------------------------- -------- ------------------------------------- -------------- -------------------------------------- ------ --------------------- -------------- -------------- ------- ------ ------ ------------ ------------- ------- -------- ------- ----- ------ -------- ------- -------- ------- --
                                                             *GPX3* (rs8177447)                                                                                                   0.09                                                                                                                              0.06                                                             0.67                                                0.53     0.38                     
                                                             CC/CT                                                                             4071                               3469     1.00                                                                                        1798   1675                  1.00                                                1648         1359          1.00                           625    435      1.00                     
                                                             TT                                                                                78                                 100      1.50                                  (1.11,         2.03)                                  44     67                    1.63           (1.11,         2.40)                 30           31            1.34    (0.80,   2.24)         4      2        0.72    (0.13,   4.05)   
  P-value (raw; adjusted)0.009, 0.02                                                                                                                                                       0.014, 0.035                                                                                                             0.27, 0.63                                          0.71, 1.00                                                                                         
  *SELS* (rs4965814)                                                                                                                                                              0.70                                                                                                                              0.43                                                             0.31                                                0.58     0.14                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                             TT                                   2042                                  1833   1                                                                                                1216                                   1136   1                                                           616    559    1                                           210     138   1                                        
                                                             TC                                   1665                                  1362   0.98                               (0.89,   1.08)                                                564                                    522    0.99                  (0.86,         1.14)                  815    626    0.88         (0.75,        1.03)            286     214   1.21   (0.91,   1.61)                    
                                                             CC                                   443                                   373    1.05                               (0.89,   1.23)                                                62                                     83     1.41                  (1.00,         1.98)                  248    205    0.93         (0.75,        1.17)            133     85    1.04   (0.73,   1.49)                    
                                                                                                  P-value (raw; adjusted) 0.58, 0.98                                                                                             0.050, 0.067                                                                       0.55, 0.90                                          0.83, 1.00                                                                                         
  *SEPN1* (rs718391)                                                                                                                           0.46                                                                                                                                           0.27                                                                      0.73                                                      0.16   0.034                             
                                                             CC/CG                                3562                                  3024   1.00                                                                                             1488                                   1369   1.00                                                        1496   1239   1.00                                        578     416   1.00                                     
                                                             GG                                   585                                   540    1.03                               (0.91,   1.18)                                                354                                    372    1.13                  (0.96,         1.33)                  181    147    0.98         (0.78,        1.24)            50      21    0.54   (0.31,   0.92)                    
                                                                                                  P-value (raw; adjusted) 0.62, 1.00                                                                                             0.14, 0.29                                                                                        0.89, 0.89                                        0.024, 0.09                                                                           
  *SEPP1* (rs230812)^[2](#ngtab1.2){ref-type="table-fn"}^                                                                                      0.16                                                                                                                                           0.57                                                                      0.01                                                      0.15                                     
                                                             AA                                   1456                                  1222   1.00                                                                                             488                                    501    1.00                                                        634    504    1.00                                        334     217   1.00                             0.005   
                                                             AC                                   1898                                  1574   0.96                               (0.86,   1.06)                                                921                                    819    0.87                  (0.75,         1.02)                  755    603    0.99         (0.84,        1.16)            222     152   1.08   (0.82,   1.42)                    
                                                             CC                                   605                                   589    1.09                               (0.95,   1.26)                                                360                                    336    0.90                  (0.74,         1.10)                  200    210    1.30         (1.03,        1.64)            45      43    1.45   (0.91,   2.30)                    
                                                             P-value (raw; adjusted) 0.21, 0.33                                                                                            0.31. 0.79                                                                                                               0.025, 0.039                                        0.12, 0.16                                                                                         
  *SEPP1* (rs6865453)^[3](#ngtab1.3){ref-type="table-fn"}^                                                                                                                                                                                                                                                                                                                                                                               \<.001                            
                                                             AA                                   1463                                  1387   1.00                                                                                             897                                    834    1.00                                                        481    476    1.00                                        85      77    1.00                                     
                                                             AC/CC                                2400                                  1937   0.90                               (0.81,   0.99)                                                832                                    802    1.03                  (0.90,         1.18)                  1066   811    0.78         (0.66,        0.91)            502     324   0.73   (0.52,   1.04)                    
                                                                                                  P-value (raw; adjusted) 0.037, 0.10                                                                                            0.65, 1.00                                                                                        0.002, 0.005                                      0.08, 0.16                                                                            
  *TXNRD1* (rs4964287)                                                                                                                         0.46                                                                                                                                           0.45                                                                      0.69                                                      0.34   0.27                              
                                                             CC/CT                                3884                                  3286   1.00                                                                                             1672                                   1561   1.00                                                        1597   1303   1.00                                        615     422   1.00                                     
                                                             TT                                   264                                   283    1.20                               (1.00,   1.43)                                                170                                    181    1.13                  (0.91,         1.42)                  81     87     1.27         (0.93,        1.75)            13      15    1.52   (0.70,   3.30)                    
                                                                                                  P-value (raw; adjusted) 0.046, 0.23                                                                                            0.26, 0.79                                                                                        0.14, 0.65                                        0.29, 0.54                                                                            
  *TXNRD2* (rs2073750)                                                                                                                         0.25                                                                                                                                           0.69                                                                      0.54                                                      0.33   0.99                              
                                                             GG                                   2169                                  1868   1.00                                                                                             1087                                   1030   1.00                                                        809    642    1.00                                        273     196   1.00                                     
                                                             GA                                   1664                                  1413   1.02                               (0.93,   1.12)                                                651                                    613    1.00                  (0.87,         1.16)                  732    607    1.06         (0.91,        1.23)            281     193   1.00   (0.77,   1.31)                    
                                                             AA                                   311                                   284    1.13                               (0.95,   1.35)                                                104                                    96     0.97                  (0.73,         1.30)                  132    140    1.38         (1.06,        1.79)            75      48    1.00   (0.66,   1.52)                    
                                                                                                  P-value (raw; adjusted) 0.17, 1.00                                                                                             0.85, 1.00                                                                                        0.018, 0.27                                       0.99, 1.00                                                                            
  *TXNRD2* (rs5992493)                                                                                                                                                                                                                                                                                                                                                                                                                   0.64                              
                                                             AA/AG                                4057                                  3454   1.00                                                                                             1789                                   1676   1.00                                                        1646   1350   1.00                                        622     428   1.00                                     
                                                             GG                                   92                                    115    1.42                               (1.08,   1.88)                                                52                                     66     1.35                  (0.93,         1.95)                  33     40     1.43         (0.89,        2.30)            7       9     1.63   (0.59,   4.48)                    
                                                                                                  P-value (raw; adjusted) 0.013, 0.20                                                                                            0.12, 1.00                                                                                        0.14, 1.00                                        0.35, 1.00                                                                            
  *TXNRD2* (rs3788314)                                                                                                                                                                                                                                                                                                                                                                                                                   0.33                              
                                                             GG                                   1158                                  941    1.00                                                                                             532                                    489    1.00                                                        443    340    1.00                                        183     112   1.00                                     
                                                             GA                                   2071                                  1770   1.06                               (0.95,   1.18)                                                910                                    838    0.98                  (0.84,         1.15)                  831    713    1.12         (0.94,        1.33)            330     219   1.09   (0.81,   1.47)                    
                                                             AA                                   918                                   853    1.14                               (1.00,   1.30)                                                399                                    412    1.10                  (0.92,         1.33)                  403    335    1.08         (0.88,        1.33)            116     106   1.42   (0.99,   2.04)                    
                                                                                                  P-value (raw; adjusted) 0.04, 0.61                                                                                             0.31, 1.00                                                                                        0.47, 1.00                                        0.055, 0.78                                                                           
  *TXNRD2* (rs3788317)                                                                                                                                                                                                                                                                                                                                                                                                                   0.34                              
                                                             GG                                   2356                                  1979   1.00                                                                                             1094                                   1017   1.00                                                        925    744    1.00                                        337     218   1.00                                     
                                                             GT                                   1554                                  1355   1.04                               (0.95,   1.15)                                                651                                    633    1.03                  (0.90,         1.19)                  656    539    1.03         (0.88,        1.20)            247     183   1.15   (0.88,   1.49)                    
                                                             TT                                   239                                   235    1.20                               (0.99,   1.45)                                                97                                     92     1.02                  (0.75,         1.37)                  97     107    1.37         (1.02,        1.84)            45      36    1.23   (0.76,   1.99)                    
                                                                                                  P-value (raw; adjusted) 0.07, 0.85                                                                                             0.91, 1.00                                                                                        0.039, 0.54                                       0.40, 1.00                                                                            

Odds Ratios (OR) and 95% Confidence Intervals (CI) adjusted for age, study, BMI during referent year, parity, and genetic ancestry (continuous).

Association for *SEPP1* rs230812 was 1.33 (95% CI 1.09,1.64; p = 0.006) for the CC genotype for women with \>28% NA ancestry. pathway P~ARTP~ is 0.04

Association for *SEPP1* rs6865453 was 0.78 (95%CI 0.67,0.90; p\<0.001) for AC/CC genotype for women with \>28% NA ancestry. *SEPP1* P~ARTP~ for \>28% NA ancestry is 0.002 and pathway P~ARTP~ is 0.04

Assessment of SNP associations by ER/PR status indicated that some SNPs were associated with breast cancer risk by ER/PR status; several genes had statistically significant P~ARTP~ values ([Table 2](#pone-0080554-t002){ref-type="table"}). *GPX1, GPX3*, and *SELS* were associated with ER-/PR+ status (P~ARTP~ = 0.002, 0.05, and 0.01, respectively). *GPX1* rs1800668 was strongly associated with increased likelihood of ER-/PR+ phenotype p\<0.001; p~adj~=0.002), while rs3448 was associated with a decreased likelihood of this phenotype (p=0.04). *GPX2* rs11623705 was associated with increased risk of ER-/PR+ (p=0.002; p~adj~ =0.006). *GPX3* rs8177447 showed a significant association with an increased likelihood of an ER-/PR+ phenotype (p=0.025; p~adj~ =0.07) as did *SELS* rs9874 (p=0.041; p~adj~=0.04) and *SELS* rs4965814 (p=0.01; p~adj~=0.02). *SELS* was also significantly associated with ER+/PR- tumors (P~ARTP~ = 0.009); *SELS* rs4965814 was positively associated with ER+/PR- (p=0.004; p~adj~=0.006). Multiple SNPs in *SEP15* showed an association with increased likelihood of ER+/PR- tumors: rs5859 (p=0.025; p~adj~=0.04), rs486133 (p=0.05; p~adj~=0.05), and rs1407131 (p=0.002; p~adj~=0.006). *TXNRD2* rs2073750 was marginally inversely associated with ER-/PR+ tumors (p=0.005; p~adj=~ 0.08) with an overall gene P~ARTP~ of 0.08. None of the genes evaluated showed a significant association with ER-/PR- tumor phenotype according to ARTP.

10.1371/journal.pone.0080554.t002

###### Associations between selenoprotein genes and breast cancer risk by ER/PR tumor status.

                                                   Controls       ER+ / PR+          ER+ / PR-                  ER- / PR+         ER- / PR-                                                                                                                               
  ---------------------- ------------------------- -------------- ----------- ------ ----------- -------------- ----------- ----- ----------- --------------- -------- ------- ------ ------------- -------- -------- ------ -------- -------- ------- ------- ------- -- --
                         *GPX1* (rs1800668)                                                      0.94                                                         0.74                                           0.002                                     0.54    0.007      
                                                   CC             1608        638    1.00                                         107         1.00                                    12            1.00                              198      1.00                       
                                                   CT             1117        425    0.91        (0.79,         1.06)             73          0.93            (0.68,   1.27)   19     2.60          (1.24,   5.47)    128    0.92     (0.73,   1.17)                      
                                                   TT             191         92     1.11        (0.85,         1.46)             20          1.43            (0.86,   2.39)   6      5.85          (2.08,   16.47)   19     0.81     (0.49,   1.33)                      
                         P-value (raw; adjusted)   0.44, 0.84                                    0.17, 0.32                                   \<.001, 0.002                           0.40, 0.75                                                                          
  *GPX1* (rs3448)                                                                                                                                                                                                                                      0.31               
                         CC                        1984           796         1.00                                          148   1.00                                         34     1.00                                   267      1.00                                
                         CT/TT                     1181           502         1.01   (0.89,      1.16)                      87    0.96        (0.72,          1.27)    9       0.46   (0.22,        0.96)    148      0.94   (0.75,   1.16)                               
                         P-value (raw; adjusted)   0.83, 0.84                                    0.77, 0.77                                   0.039, 0.039                            0.55, 0.75                                                                          
  *GPX2* (rs11623705)                                                                0.31                                                     0.71                                                  0.30                                       0.23    0.61               
                                                   GG             2500        1015   1.00                                         192         1.00                                    36            1.00                              340      1.00                       
                         GT                        628            271         1.05   (0.89,      1.23)                      36    0.74        (0.51,          1.08)    4       0.44   (0.16,        1.26)    74       0.87   (0.67,   1.14)                               
                         TT                        36             11          0.72   (0.36,      1.43)                      7     2.35        (1.02,          5.42)    3       7.19   (2.06,        25.06)   1        0.22   (0.03,   1.63)                               
                         P-value (raw; adjusted)   0.35, 0.81                                    0.045, 0.13                                  0.002, 0.006                            0.14, 0.26                                                                          
  *GPX3* (rs8177447)                                                                 0.56                                                     0.30                                                  0.048                                      0.17    0.056              
                         CC                        2270           926         1.00                                          180   1.00                                         24     1.00                                   297      1.00                                
                         CT                        827            323         0.92   (0.79,      1.07)                      48    0.71        (0.51,          0.98)    16      1.86   (0.98,        3.56)    100      0.91   (0.72,   1.16)                               
                         TT                        68             49          1.79   (1.23,      2.62)                      7     1.38        (0.62,          3.08)    3       4.12   (1.19,        14.24)   18       1.94   (1.13,   3.31)                               
                         P-value (raw; adjusted)   0.003, 0.007                                  0.43, 0.68                                   0.025, 0.066                            0.016, 0.04                                                                         
  *SELS* (rs9874)                                                                    0.21                                                     0.009                                                 0.01                                       0.71    0.07               
                         AA                        2355           993         1.00                                          168   1.00                                         26     1.00                                   305      1.00                                
                         AG/GG                     810            305         0.88   (0.76,      1.03)                      67    1.15        (0.86,          1.55)    17      1.91   (1.03,        3.54)    109      1.03   (0.81,   1.30)                               
                         P-value (raw; adjusted)   0.10, 0.16                                    0.35, 0.35                                   0.04, 0.04                              0.83, 0.99                                                                          
  *SELS* (rs4965814)                                                                                                                                                                                                                                   0.005              
                         TT                        1716           719         1.00                                          108   1.00                                         14     1.00                                   215      1.00                                
                         TC/CC                     1450           579         1.02   (0.89,      1.17)                      127   1.51        (1.15,          2.00)    29      2.37   (1.22,        4.59)    199      1.06   (0.85,   1.31)                               
                         P-value (raw; adjusted)   0.81, 0.81                                    0.004, 0.006                                 0.011, 0.017                            0.62, 0.99                                                                          
  *SEP15* (rs5859)                                                                                                                                                                                                                                     0.87               
                         CC                        1878           721         1.00                              0.37        131   1.00                                 0.84    23     1.00                            0.77   218      1.00                     0.92       
                         CT                        925            376         1.04   (0.89,      1.20)                      54    0.82        (0.59,          1.14)    13      1.19   (0.60,        2.38)    111      1.03   (0.81,   1.31)                               
                         TT                        109            53          1.23   (0.88,      1.73)                      15    1.93        (1.09,          3.42)    1       0.85   (0.11,        6.37)    13       1.05   (0.58,   1.89)                               
                         P-value (raw; adjusted)   0.23, 0.63                                    0.025, 0.04                                  0.87, 1.00                              0.88, 1.00                                                                          
  *SEP15* (rs486133)                                                                                                                                                                                                                                   0.86               
                         TT                        2138           862         1.00                                          160   1.00                                         30     1.00                                   288      1.00                                
                         TC                        925            385         1.02   (0.88,      1.17)                      61    0.88        (0.64,          1.19)    12      0.95   (0.48,        1.87)    114      0.93   (0.74,   1.17)                               
                         CC                        103            51          1.19   (0.84,      1.69)                      14    1.80        (1.00,          3.24)    1       0.76   (0.10,        5.64)    13       0.97   (0.53,   1.75)                               
                         P-value (raw; adjusted)   0.32, 0.63                                    0.05, 0.05                                   0.79, 1.00                              0.91, 1.00                                                                          
  *SEP15* (rs1407131)                                                                                                                                                                                                                                  0.69               
                         TT                        2478           987         1.00                                          187   1.00                                         36     1.00                                   324      1.00                                
                         TC                        648            293         1.11   (0.95,      1.30)                      39    0.79        (0.55,          1.12)    6       0.64   (0.27,        1.54)    87       1.04   (0.80,   1.33)                               
                         CC                        40             18          1.14   (0.65,      2.01)                      9     3.21        (1.52,          6.79)    1       1.81   (0.24,        13.69)   4        0.78   (0.28,   2.21)                               
                         P-value (raw; adjusted)   0.64, 0.65                                    0.002, 0.006                                 0.575, 1.00                             0.64, 1.00                                                                          
  *TXNRD1* (rs5018287)                                                        0.12                                                0.76                                                0.76                                            0.94     0.15                       
                         GG                        913            414         1.00                                          68    1.00                                         11     1.00                                   121      1.00                                
                         GA                        1571           631         0.87   (0.75,      1.01)                      119   0.98        (0.72,          1.34)    21      1.11   (0.53,        2.32)    198      0.95   (0.75,   1.21)                               
                         AA                        678            252         0.81   (0.67,      0.98)                      48    0.92        (0.62,          1.35)    11      1.39   (0.60,        3.23)    96       1.09   (0.82,   1.45)                               
                         P-value (raw; adjusted)   0.030, 0.15                                   0.66, 1.00                                   0.45, 0.87                              0.56, 1.00                                                                          
  *TXNRD1* (rs7962759)                                                                                                                                                                                                                         0.41                       
                         CC                        2233           873         1.00                                          163   1.00                                         32     1.00                                   289      1.00                                
                         CG                        848            375         1.09   (0.94,      1.26)                      66    1.05        (0.77,          1.42)    7       0.59   (0.26,        1.37)    113      1.04   (0.82,   1.31)                               
                         GG                        85             50          1.43   (1.00,      2.06)                      6     0.96        (0.41,          2.24)    4       3.60   (1.21,        10.73)   13       1.21   (0.66,   2.21)                               
                         P-value (raw; adjusted)   0.05, 0.21                                    0.92, 1.00                                   0.02, 0.11                              0.54, 1.00                                                                          
  *TXNRD2* (rs1044732)                                                        0.36                                                0.93                                                0.08                                            0.80     0.20                       
                         AA                        2228           884         1.00                                          148   1.00                                         35     1.00                                   264      1.00                                
                         AG/GG                     689            271         0.96   (0.82,      1.13)                      52    1.11        (0.80,          1.55)    2       0.19   (0.04,        0.78)    81       0.98   (0.75,   1.28)                               
                         P-value (raw; adjusted)   0.66, 1.00                                    0.54, 1.00                                   0.02, 0.30                              0.88, 1.00                                                                          
  *TXNRD2* (rs3788305)                                                                                                                                                                                                                         0.28                       
                         AA                        944            423         1.00                                          70    1.00                                         16     1.00                                   129      1.00                                
                         AG/GG                     2220           875         0.87   (0.75,      1.00)                      165   1.00        (0.75,          1.34)    27      0.71   (0.38,        1.33)    286      0.94   (0.75,   1.17)                               
                         P-value (raw; adjusted)   0.045, 0.68                                   0.99, 1.00                                   0.28, 1.00                              0.58, 1.00                                                                          
  *TXNRD2* (rs2073750)                                                                                                                                                                                                                         0.09                       
                         GG                        1713           707         1.00                                          125   1.00                                         32     1.00                                   223      1.00                                
                         GA/AA                     1448           590         1.01   (0.89,      1.16)                      108   1.03        (0.79,          1.35)    11      0.37   (0.19,        0.75)    191      0.99   (0.80,   1.22)                               
                         P-value (raw; adjusted)   0.84, 1.00                                    0.81, 1.00                                   0.005, 0.08                             0.91, 1.00                                                                          

Odds Ratios (OR) and 95% Confidence Intervals (CI) adjusted for age, study, BMI during referent year, parity, and genetic ancestry (continuous); data from 4-CBCS and SFBCS

Five SNPs, *GPX3* rs2070593 (p=0.002), *GPX4* rs2074451 (p=0.046), *SELS* rs9874 (p=0.029), *TXNRD1* rs17202060 (p=0.007) and *TXNRD2* rs7322262 (p=0.025), significantly interacted with DOBS to alter breast cancer risk ([Table 3](#pone-0080554-t003){ref-type="table"}). Of these SNPs, only *TXNRD2* rs732262 (p~adj~ =0.38) did not remain statistically significantly associated with breast cancer risk after multiple comparison adjustment.

10.1371/journal.pone.0080554.t003

###### Associations between dietary oxidative balance score (DOBS) and selenoprotein genes and risk of breast cancer.

                                  Dietary Oxidative Balance Score^[1](#ngtab3.1){ref-type="table-fn"}^                                                                                                                               
  ----------------------- ------- ---------------------------------------------------------------------- ----- ------ -------------- ----- ----- ------ -------------- ------ ----- ------ -------------- ----- ----- -------------- --------------
  *GPX3* (rs2070593)                                                                                                                                                                                                  0.002, 0.005   
                          GG      580                                                                    589   1.00                  596   521   0.88   (0.75, 1.04)   695    542   0.79   (0.67, 0.93)   506   463   0.92           (0.78, 1.10)
                          GA/AA   350                                                                    369   1.08   (0.89, 1.30)   337   337   1.04   (0.86, 1.26)   508    381   0.79   (0.66, 0.94)   421   262   0.66           (0.54, 0.80)
  *GPX4* (rs2074451)                                                                                                                                                                                                  0.046, 0.046   
                          GG/GT   741                                                                    730   1.00                  759   630   0.87   (0.75, 1.01)   928    738   0.83   (0.72, 0.96)   705   562   0.84           (0.72, 0.97)
                          TT      144                                                                    147   1.00   (0.78, 1.29)   124   143   1.13   (0.87, 1.47)   199    121   0.61   (0.47, 0.78)   160   110   0.68           (0.52, 0.89)
  *SELS* (rs9874)                                                                                                                                                                                                     0.029, 0.048   
                          AA      691                                                                    740   1.00                  706   656   0.89   (0.76, 1.03)   926    717   0.75   (0.65, 0.86)   734   558   0.73           (0.62, 0.85)
                          AG      223                                                                    216   0.88   (0.71, 1.10)   215   186   0.81   (0.64, 1.01)   270    192   0.67   (0.54, 0.83)   180   152   0.81           (0.63, 1.03)
                          GG      16                                                                     6     0.34   (0.13, 0.88)   18    19    0.95   (0.49, 1.83)   10     16    1.45   (0.65, 3.24)   17    18    1.02           (0.52, 2.00)
  *TXNRD1* (rs17202060)                                                                                                                                                                                               0.007, 0.034   
                          CC/CT   763                                                                    841   1.00                  788   721   0.85   (0.74, 0.98)   1018   778   0.71   (0.62, 0.82)   781   605   0.72           (0.62, 0.83)
                          TT      165                                                                    121   0.68   (0.52, 0.88)   152   140   0.86   (0.67, 1.11)   188    147   0.76   (0.60, 0.97)   150   123   0.81           (0.62, 1.05)
  *TXNRD2* (rs732262)                                                                                                                                                                                                 0.025, 0.378   
                          GG      663                                                                    644   1.00                  681   566   0.87   (0.75, 1.02)   821    633   0.82   (0.70, 0.95)   612   507   0.87           (0.74, 1.02)
                          GA      207                                                                    210   1.08   (0.86, 1.35)   182   187   1.14   (0.90, 1.44)   276    206   0.82   (0.66, 1.02)   233   150   0.73           (0.58, 0.93)
                          AA      15                                                                     23    1.78   (0.91, 3.46)   20    20    1.14   (0.60, 2.16)   30     20    0.75   (0.42, 1.34)   20    15    0.83           (0.42, 1.64)

DOBS consists of alcohol (pro-oxidant), vitamins C and E, beta carotene, folic acid, and dietary fiber (anti-oxidants).

Odds Ratios (OR) and 95% Confidence Intervals (CI) adjusted for age, genetic ancestry, study center, BMI during referent year, and parity.

Multiple genes and SNPs in our analysis showed an association with breast cancer survival ([Table 4](#pone-0080554-t004){ref-type="table"}). *GPX4* was significantly associated with better breast cancer survival among those with the highest NA ancestry (P~ARTP~ = 0.05). *GPX4* ~*GT/TT*~ rs2074451 showed a marginal inverse association with survival for individuals among women with \>28% NA ancestry (p=0.055; p~adj~ = 0.055; p interaction=0.06). Several SNPs in *TXNRD2* were associated with survival prior to adjustment for multiple comparisons. Additionally, *TXNRD2* ~*AA*~ rs3788314 and *TXNRD2* ~*CT/TT*~ rs4333017 showed significant interaction across genetic ancestry (p~int~=0.035 and p~int~=0.017, respectively).

10.1371/journal.pone.0080554.t004

###### Association between selenoprotein genes and survival by ancestry.

                                                                Overall              0 - 28% Native American Ancestry                29 - 100% Native American Ancestry                                                                                       
  ---------------------- -------------------------------------- ------------- ------ ---------------------------------- ------------ ------------------------------------ ------------- ------ ------------ ------- -- ----------- ------ -------- ------- -- -------
  *GPX4* (rs2074451)                                                                 0.46                                                                                                      0.55d                                      0.05     0.06       
                         GG                                     69 / 5878     1.00                                                                                        36 / 3476     1.00                           33 / 2402   1.00                       
                         GT/TT                                  127 / 12780   0.90   (0.67,                             1.21)                                             91 / 8514     1.13   (0.76,       1.67)      36 / 4265   0.62   (0.39,   1.01)      
                         P-value (raw, adjusted) 0.50, 0.50                                                             0.55, 0.55                                                             0.06, 0.06                                                     
  *SEPW1* (rs3786777)                                                                0.28                                                                                                      0.06                                       0.81     0.13       
                         TT                                     57 / 6219     1.00                                                                                        26 / 3389     1.00                           31 / 2830   1.00                       
                         TG/GG                                  169 / 15030   1.28   (0.94,                             1.73)                                             107 / 9331    1.65   (1.07,       2.54)      62 / 5700   0.99   (0.64,   1.53)      
                         P-value (raw, adjusted) 0.11, 0.21                                                             0.02, 0.04                                                             0.97, 0.97                                                     
  *TXNRD2* (rs9606173)                                                               0.24                                                                                                      0.76                                       0.09     0.63       
                         AA                                     168 / 14566   1.00                                                                                        105 / 9429    1.00                           63 / 5137   1.00                       
                         AT/TT                                  61 / 6816     0.73   (0.54,                             0.99)                                             30 / 3355     0.80   (0.53,       1.20)      31 / 3462   0.68   (0.44,   1.06)      
                         P-value (raw, adjusted) 0.04, 0.57                                                             0.28, 1.00                                                             0.09, 0.97                                                     
  *TXNRD2* (rs732262)                                                                                                                                                                                                                              0.15       
                         GG                                     164 / 14336   1.00                                                                                        111 / 10086   1.00                           53 / 4250   1.00                       
                         GA/AA                                  32 / 4322     0.63   (0.43,                             0.94)                                             16 / 1905     0.87   (0.52,       1.48)      16 / 2417   0.47   (0.27,   0.83)      
                         P-value (raw, adjusted) 0.02, 0.33                                                             0.62, 1.00                                                             0.01, 0.15                                                     
  *TXNRD2* (rs3788314)                                                                                                                                                                                                                                        
                         GG                                     69 / 5595     1.00                                                                                        39 / 3530     1.00                           30 / 2065   1.00                       0.035
                         GA                                     108 / 10911   0.86   (0.63,                             1.16)                                             58 / 6296     0.86   (0.57,       1.30)      50 / 4614   0.84   (0.52,   1.34)      
                         AA                                     51 / 4836     0.91   (0.63,                             1.31)                                             38 / 2931     1.26   (0.80,       1.99)      13 / 1905   0.50   (0.26,   0.97)      
                         P-value (raw, adjusted) 0.61, 1.00 .                                                           0.31, 1.00                                                             0.04, 0.52                                                     
  *TXNRD2* (rs3788317)                                                                                                                                                                                                                             0.04       
                         GG                                     133 / 11991   1.00                                                                                        74 / 7409     1.00                           59 / 4582   1.00                       
                         GT                                     84 / 8163     0.94   (0.71,                             1.24)                                             51 / 4744     1.04   (0.72,       1.49)      33 / 3419   0.82   (0.53,   1.26)      
                         TT                                     12 / 1228     0.86   (0.48,                             1.56)                                             10 / 630      1.58   (0.81,       3.07)      2 / 598     0.27   (0.06,   1.10)      
                         P-value (raw, adjusted) 0.62, 1.00                                                             0.18, 1.00                                                             0.07, 0.81                                                     
  *TXNRD2* (rs4333017)                                                                                                                                                                                                                                        
                         CC                                     180 / 16994   1.00                                                                                        107 / 9640    1.00                           73 / 7354   1.00                       0.017
                         CT/TT                                  49 / 4388     1.13   (0.82,                             1.56)                                             28 / 3143     0.85   (0.56,       1.29)      21 / 1245   1.86   (1.13,   3.06)      
                         P-value (raw, adjusted) 0.46, 1.00                                                             0.43, 1.00                                                             0.02, 0.22                                                     

Hazard Ratios (HR) and 95% Confidence Intervals (CI) among primary invasive cases; adjusted for age, study, BMI during referent year, parity, genetic ancestry, and SEER summary stage. Includes data from the 4-CBCS and SFBCS.

Discussion {#s4}
==========

Based on ARTP results, *GPX3* was borderline statistically significantly associated with breast cancer risk for all women and for women with lower levels of NA ancestry specifically. *SEPP1* showed a statistically significant interaction by NA ancestry, with a strong association with breast cancer risk among women with higher NA ancestry. Some differences in association were observed by ER/PR tumor status. *GPX1, GPX3*, and *SELS* were significantly associated with ER-/PR+ tumors and *SELS* was significantly associated with ER+/PR- tumors. *GPX4* was significantly associated with survival among those with higher NA ancestry and *SEPW1* was marginally associated with survival among women in the low NA ancestry group. Although we hypothesized that DOBS would modify associations with selenoprotein genes, only one SNP in *GPX4*, *SELS*, and *TXNRD1* that interacted with DOBS remained statistically significantly associated with breast cancer after adjustment for multiple comparisons.

Among the genes evaluated in this study, only *GPX3* showed a borderline significant association overall as determined by the P~ARTP~, and *GPX3* rs8177447 was statistically significant after adjustment for multiple comparisons. This SNP is in high LD with rs3792797 and has been associated with Barrett's Esophagus \[[@B29]\] (see [table 5](#pone-0080554-t005){ref-type="table"} for comparison of findings of this study to other information on SNPs). *GPX3* is one of multiple glutathione peroxidases, all of which are selenoproteins that play a role in catalyzing the reduction of hydrogen peroxides to minimize oxidative stress which can damage cells \[[@B10]\]. This enzyme acts as an efficient antioxidant in the plasma and has previously been linked to other diseases associated with oxidative stress \[[@B10]\]. Our study indicates that in addition to an important role in development of these cancers, *GPX3* may also play a role in the development and progression of breast cancer.

10.1371/journal.pone.0080554.t005

###### LD comparison of SNPs associated with breast cancer risk or with survival to other SNPs reported in literature as associated with cancer, serum markers, gene expression, or identified as being non-synonymous (NS) coding SNPs.

  **Gene**   **SNP**     **Location/Coding type**      **Functional SNP**                               **LD^1^ r^2^**
  ---------- ----------- ----------------------------- ------------------------------------------------ ----------------
  *GPX3*     rs8177447   intronic enhancer             rs4958872 \[[@B6],[@B29]\]                       0.67
                                                       rs3792797 \[[@B6]\]                              0.95
                                                       rs3828599 \[[@B47]\]                             NA
                                                       rs3805435 \[[@B47]\]                             NA
  *GPX4*     rs2074451   3\' downstream                rs713041 \[[@B3],[@B40],[@B42],[@B48],[@B49]\]   0.59
                                                       rs2075710 \[[@B36]\]                             0.27
                                                       rs2074452 \[[@B36]\]                             0.34
                                                       rs757229 \[[@B42]\]                              0.72
  *SELS*     rs4965814   intronic                      rs4965373 \[[@B40]\]                             0.08
                                                       rs34713741 \[[@B4]\]                             0.001
  *SEPP1*    rs230812    3\' downstream                rs3877899\[[@B3],[@B34],[@B47],[@B48]\] NS       0.31
                                                       rs7579 \[[@B3],[@B34],[@B49]\]                   0.34
                                                       rs230813 \[[@B4],[@B38]\]                        1.00
                                                       rs230819 \[[@B4],[@B38]\]                        0.70
                                                       rs11959466 \[[@B35]\]                            0.04
                                                       rs13168440 \[[@B35]\]                            0.19
                                                       rs3797310 \[[@B36]\]                             0.32
                                                       rs12055266 \[[@B37],[@B47]\]                     0.32
             rs6865453   5\' upstream                  rs3877899 NS                                     0.14
                         promoter                      rs7579                                           0.96
                         /regulatory region            rs230813                                         0.32
                                                       rs230819                                         0.42
                                                       rs11959466                                       0.12
                                                       rs13168440                                       0.09
                                                       rs3797310                                        1.00
                                                       rs12055266                                       0.92
  *SEPW1*    rs3786777   intronic enhancer                                                              NA
  *TXNRD1*   rs4964287   splicing regulation           rs1128446 \[[@B36]\]                             0.71
                         coding; synonymous            rs4964785 \[[@B36]\]                             0.52
                                                       rs7310505 \[[@B3]\]                              0.08
  *TXNRD2*   rs9606173   intronic enhancer             rs9605031 \[[@B40]\]                             0.02
                                                       rs1139793 \[[@B50]\] NS                          0.07
                                                       rs5992495 NS                                     0.006
                                                       rs5748469 NS                                     0.003
             rs732262    intronic enhancer             rs9605031                                        0.11
                                                       rs1139793 NS                                     0.13
                                                       rs5992495 NS                                     0.12
                                                       rs5748469 NS                                     0.18
             rs3788314   intronic                      rs9605031                                        0.27
                                                       rs1139793 NS                                     \<0.001
                                                       rs5992495 NS                                     0.28
                                                       rs5748469 NS                                     0.18
             rs3788317   intronic                      rs9605031                                        0.10
                                                       rs1139793 NS                                     0.03
                                                       rs5992495 NS                                     0.53
                                                       rs5748469 NS                                     0.001
             rs5992493   intronic enhancer             rs9605031                                        0.05
                                                       rs1139793 NS                                     0.12
                                                       rs5992495 NS                                     1.00
                                                       rs5748469 NS                                     0.12
             rs4333017   intronic                      rs9605031                                        0.003
                                                       rs1139793 NS                                     0.006
                                                       rs5992495 NS                                     0.04
                                                       rs5748469 NS                                     0.001

LD determined for SNPs using SNAP, from the Broad Institute, with the 1000 genome data option; in some instance LD results were not available (NA)

Other studies have indicated that glutathione peroxidases may be associated with breast cancer risk, specifically *GPX1* \[[@B14],[@B30]\], a cytosolic antioxidant \[[@B31]\]. A meta-analysis of six case-control studies of the Pro198Leu polymorphism (rs1050450) in *GPX1*, did not see an association between breast cancer risk in Caucasians, although they did see a strong increased risk of breast cancer among African women \[[@B32]\]. Likewise, Cox and colleagues did not see an association between this SNP and breast cancer risk \[[@B33]\]. In a recent study by Meplan, *GPX1* rs1050450 was shown to interact with hormone therapy to alter risk of breast cancer \[[@B34]\]. Our study did not show an association with breast cancer risk and *GPX1*. We did however, detect an association between *GPX1* and ER-/PR+ breast tumors; however this represents a small group of women and could be a chance finding.

*SEPP1* SNPs have been associated with a variety of cancers, including prostate \[[@B35],[@B36]\], lung \[[@B2]\], and colorectal \[[@B3],[@B37]\] cancer. Therefore, we evaluated three candidate *SEPP1* SNPs that have been associated with oxidative stress and cancer \[[@B6],[@B38]\] and are in high LD with other functional SNPs (see [Table 5](#pone-0080554-t005){ref-type="table"}). SEPP1 is the major selenoprotein in plasma, acting as a selenium transport protein \[[@B13]\]. SEPP1 has been shown to behave as an antioxidant \[[@B13]\] and estrogen has been shown to increase hepatic SEPP1 concentrations \[[@B39]\], providing biological support for the observed associations between *SEPP1* SNPs and cancer risk. Support for *SEPP1* as an antioxidant comes from earlier findings that in human plasma the SEPP1 protein is involved in the degradation of peroxynitrite, which plays a role in inflammatory toxicity \[[@B31]\]. Additionally, associations between serum selenium levels and thioredoxin reductase activity have been correlated with *SEPP1* rs3877899 \[[@B40]\], thereby establishing a further link between *SEPP1* and the antioxidant activities of selenoproteins. Our analysis failed to find an association between our candidate SNP, *SEPP1* rs3877899, that was previously linked to breast cancer \[[@B26]\] and is a non-synonymous coding SNP. In our analysis of two other *SEPP1* SNPs, rs230812 and rs6865453, we found an association with breast cancer risk among women with higher NA ancestry. *SEPP1* rs230812 is in high LD with rs230813 and rs230819 (see [Table 5](#pone-0080554-t005){ref-type="table"}) which have been associated with oxidative stress \[[@B6],[@B38]\]. *SEPP1* was the only significant gene associated with breast cancer risk among women with greater NA ancestry which was significantly different than the risk observed for women with low NA ancestry. In this study, a large percentage of women with greater NA ancestry were part of the Mexico City Breast Cancer Study and it is possible that differences in selenium levels in food could exist between those women and women in the United States. If women from Mexico had lower serum selenium it is possible that *SEPP1* could have a greater effect on risk.

We found that some selenoproteins were associated with tumor ER/PR status. Based on our analysis of gene P~ARTP~, *GPX1, GPX3*, and *SELS* were associated with ER-/PR+ tumor status, while *SELS* was also associated with ER+/PR- tumors. Additionally, several individual SNPs were associated with ER/PR status after adjusting for multiple comparisons. An earlier study found that glutathione peroxidase expression was associated with PR- status, as well as increased patient mortality \[[@B41]\]. The differences in results may be explained by the fact that the earlier study looked solely at expression levels of glutathione peroxidases, while our study looked at gene and SNP interactions without looking at expression of proteins. Other studies have shown links between selenoproteins and estrogen. GPX1 messenger RNA has been shown to be up-regulated in the presence of estrogen \[[@B42]\]. TXNRD1 has been shown to be an important modular of estrogen signaling through the estrogen receptor response elements \[[@B43]\]

We also observed associations between selenoprotein SNPs and survival. Notably, *GPX4* rs2074451 showed marginally significant interaction with NA ancestry and having a T allele was associated with decreased likelihood of dying from breast cancer among women with \>28% NA ancestry. This is in agreement with study by Udler and colleagues \[[@B42]\], where they reported that *GPX4* rs757229 and rs713041 were associated with a greater risk of all-cause mortality after diagnosis with breast cancer. *GPX4* rs2074451 is highly correlated with these SNPs (see [Table 5](#pone-0080554-t005){ref-type="table"}). Additionally, three SNPs in *TXNRD2* (rs3788314, rs3788317, and rs4333017) showed significant differences in survival by ancestry. TXNRD2 has been associated with oxidative stress and our previous analysis of dietary factors of oxidative stress found the strongest associations among women with higher NA ancestry \[[@B22]\]. Udler did not observe a significant association between any of the *TXNRD1* or *TXNRD2* SNPs and breast cancer survival \[[@B42]\].

Given their role as antioxidants and mediators of oxidative stress, we evaluated selenoprotein SNPs for interactions with DOBS and found that *GPX3* rs2070593, *GPX4* rs2074451, *SELS* rs9874, and *TXNRD1* rs17202060 showed significant interactions with DOBS after adjusting for multiple comparisons. Oxidative stress and high levels of reactive oxidative species have been suggested to play an important role in breast cancer development because free radicals damage DNA, thereby decreasing genomic integrity \[[@B44]\]. Our observed interactions with DOBS indicate that high DOBS may reduce breast cancer risk in individuals with high-risk genotypes.

The selenoprotein genes analyzed in this study were selected due to previous studies reporting on their roles in regulating oxidative stress and/or carcinogenesis; however, the majority of the genes and SNPs had not been studied in relation to breast cancer. [Table 5](#pone-0080554-t005){ref-type="table"} compares SNPs associated with breast cancer risk and survival in our study, to those reported in the literature in alter cancer risk, influence oxidative stress, or influence gene expression. Selenium levels have been associated with breast cancer \[[@B45]\], along with SNPs in *GPX1* \[[@B14]\] and *GPX4* \[[@B46]\]. We did not find evidence for an association with breast cancer risk for these particular glutathione peroxidases, yet we found that *GPX3* was associated marginally with breast cancer risk and *SEPP1* was associated with risk among women with higher NA ancestry. *GPX4* was associated with breast cancer survival. Glutathione peroxidases carry out similar functions and have similar mechanisms; they contain a conserved catalytic triad of Sec, Gln, and Trp that acts by sequential oxidation and reduction of the Sec residue during catalysis \[[@B10]\]. The primary difference between the different glutathione peroxidases appears to be tissue distribution and cellular location; therefore, it is highly likely that multiple glutathione peroxidases participate in the antioxidant defense system against oxidative damage.

Our study has two primary limitations. First, we only evaluated a subset of the known selenoproteins and did not evaluate any DIOs or SPS2s. Since these selenoproteins, along with others, play a role in limiting oxidative stress it is possible that they may be associated with breast cancer risk. Our second limitation was in our analysis of ER/PR status and survival where we were unable to include data from Mexico. While our study population was large, the sample sizes for the different ER/PR subtypes were small, thereby decreasing the statistical power of our analysis. Nevertheless, our study has multiple strengths: our analytic approach that evaluated the pathway as a whole, and our analysis of genes beyond individual SNPs via P~ARTP~. These strengths allowed us to show that both *GPX3* and *SEPP1* were associated with breast cancer; these associations warrant further study in other populations. An additional strength is our genetically admixed population that allowed us to evaluate associations across the spectrum of European to Native ancestry.

While we observed few significant associations between selenoprotein genes and breast cancer risk, *GPX3* was marginally significant among women with lower NA ancestry and *SEPP1* was statistically significant among women with higher NA ancestry. Additionally, several genes were associated with ER/PR status. While we hypothesized that selenoprotein genes would interact with DOBS, only four SNPs significantly interacted with DOBS after adjustment for multiple comparisons. In conclusion, this study provides limited support for an association between selenoprotein genes and risk of breast cancer.
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